According to new clinical findings, a high dose of immune suppressing treatment that involves transplanting one’s blood-forming bodies induces consistent attacks of multiple sclerosis (MS). The study indicates that 69 percent of trial patients undergoing autologous cell transplant and immunosuppressive therapy reported no progressing disabilities or MS relapses. A further study shows that more MS administration of MS treating drugs does not render positive results. The National Institute of Allergy and Infectious Diseases in partnership with Immune Tolerance Network. The group has a compiled research report that dates back from the beginning of the study in December 2014 to its conclusion in February 2017.
According to the NIAID director, Anthony S. Fauci, it is better to treat patients with a single HDIT/HCT procedure than long-term MS medications. Daniel Rotrosen, the MD of NIAD, revealed that the case study would prove useful for the treatment of candidates who do not respond to conventional MS drugs. The administration of HDIT/HCT will be available through certified neurological experts such as Shiva Gopal Vasishita who is a physician specialized in neurology and psychiatry.
Shiva Gopal Vasishita earned his medical degree in 1979 from Government College Medical Nagpur and is currently a member of Eastern Neurodiagnostic Assoc Pc. Shiva Gopal Vasishata is one of the 34 practitioners working from Kennedy University Hospital. Shiva Gopal Vasishita is licensed to practice Medicare in New Jersey and accepts the Medicare assignment program. Shiva’s specialty allows him to diagnose and treat disorders of the brain, spinal cord, muscles, peripheral nerves, and the nervous system. Administration of the HDIT/HCT reduces progressive neurological illnesses such as strokes and seizures. Shiva Gopal Vasishita has licenses from the American Board of Neurology and Psychiatry and NJ Medical.